Turning Point Therapeutics, Inc. announced the following 2021 milestone targets for its pipeline of four drug candidates, including data updates from multiple clinical studies and the initiation of new clinical studies: Present updated data from the TRIDENT-1 study in TKI-naive patients with ROS1-positive advanced non-small cell lung cancer in a mini-oral presentation on January 31, 2021 at the World Conference on Lung Cancer; Provide an update on the overall Phase 2 TRIDENT-1 registrational study timeline in the first quarter of 2021; Initiate the Phase 2 TRIDENT-2 combination study in patients with KRAS mutant NSCLC mid-year 2021; and Provide clinical data updates from certain cohorts of the Phase 2 TRIDENT-1 study in the second half of 2021. Initiate the Phase 2 SHIELD-2 study of TPX-0022 in combination with an epidermal growth factor receptor tyrosine kinase inhibitor in the second half of 2021; and Provide a clinical data update from the Phase 1 portion of the SHIELD-1 study in the second half of 2021. Report early interim data from initial patients enrolled in the dose finding portion of the TPX-0046 Phase 1 study in the first half of 2021. Submit the investigational new drug application for TPX-0131 in the first quarter of 2021; and Initiate a Phase 1 clinical study of TPX-0131 in the first half of 2021. Outline research strategy, focus and milestones for future development candidates in the second half of 2021.